November 12, 2024
(L-R) CooperVision’s Dr. Felicia Timmermann, Dr. Priscilla Chang, Dr. Justin Kwan, and Dr. Leah Johnson Photo Credit: CooperVision
INDIANAPOLIS — During the American Academy of Optometry’s 2024 Annual Meeting, CooperVision‘s Myopia Luminaries Forum coincided with the fifth anniversary of MiSight 1 day contact lenses earning FDA approval.*
“Celebrating this five-year milestone with some of the brightest minds in the industry was a meaningful way to honor this journey,” said Justin Kwan, OD, FAAO, Head, Myopia Management, CooperVision. “Being the first to market is never easy, but when it comes to children’s eye health, it’s essential. Taking the time to reflect on the tremendous work of the past five years and building excitement for the future was the perfect way to kick off Academy this year.”*¶1
Prominent myopia experts who spoke at the event included:
- Arthur Bradley, PhD, CooperVision Research Fellow, shared insights into the latest advancements in myopia research.
- Maria Liu, PhD, associate professor at the University of California, Berkeley, presented key scientific updates followed by an engaging Q&A session.
- Carlee Young, OD, FAAO, shared practical insights and real-world results about the impact of myopia management.
 |
 |
Dr. Justin Kwan (left) and Dr. Katherine Schuetz (right) interview parents and children, sharing how MiSight 1 day has positively impacted their daily lives.
Katherine Schuetz, OD, then facilitated a panel that featured interviews with both parents and children, offering authentic feedback on how MiSight 1 day has positively influenced their daily lives and shaped their future vision health.
The event was designed around an elementary school theme, which tied into the “CooperVision Elementary” booth on the Academy show floor. This playful yet purposeful concept highlighted the necessity of early intervention in childhood myopia, reinforcing the idea that timely action is crucial for effective management and long-term eye health in young patients.2
References
*Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†ActivControl technology in MiSight 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.
‡MiSight 1 day shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for six years. n=40.
¶ Compared to a single-vision 1 day lens over a three-year period.
1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
2. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
